This week, the team discuss the deal between UK's National Health Service and Biogen prompting the successful reimbursement of Biogen’s Spinraza as a treatment for spinal muscular atrophy and Solid Biosciences’ clinical update on its Duchenne Muscular Dystrophy gene therapy product SGT-001.
Presenter: Aparna Krishnan
Contributor: Max Rex
Producer: Aparna Krishnan
Send in a voice message: https://anchor.fm/rare-diseases-weekly-roundup/message
Create your
podcast in
minutes
It is Free